×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!

PAREXEL Strategic Partnerships 2014 Report

March 31, 2014
In this video, Mark A. Goldberg, M.D., President and Chief Operating Officer, of PAREXEL, reveals why more than half of biopharmaceutical companies surveyed use a Strategic Partnership model. Learn more about why the Strategic Partnership model is perceived as the most effective biopharmaceutical outsourcing approach in meeting key sponsor needs: The model is considered particularly effective in enabling greater cost predictability, strategic management of the R&D portfolio and management of capacity gaps. Among companies surveyed, more than half now use a Strategic Partnership model: 54 percent of North American biopharmaceutical companies engage in Strategic Partnerships, while 50 percent in Europe and 53 percent in Asia now use this approach. Positive perceptions of outsourcing effectiveness within the biopharmaceutical industry have increased significantly in the last three years: This increase has occurred across all geographies and with sponsors of all sizes. Download the report at http://www.parexel.com/experience/delivery-models/strategic-partnerships/
Previous Video
Conal Burgess, Corporate VP, talks about PAREXEL's Strategic Partnerships 2014 Report
Conal Burgess, Corporate VP, talks about PAREXEL's Strategic Partnerships 2014 Report

Conal Burgess talks about PAREXEL's latest Strategic Partnerships report from the floor of Partnerships in ...

Next Video
PAREXEL: Your Journey. Our Mission. ®
PAREXEL: Your Journey. Our Mission. ®

http://www.PAREXEL.com Drug development today is more than a process. It's a journey. At PAREXEL, we are c...